Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVX NASDAQ:PCVX NASDAQ:PRAX NASDAQ:RARE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$123.78+5.7%$116.89$5.59▼$148.83$9.29B0.84834,291 shs1.27 million shsPCVXVaxcyte$55.60-4.9%$58.67$28.09▼$65.00$8.45B1.31.09 million shs2.17 million shsPRAXPraxis Precision Medicines$333.30-1.3%$318.06$34.89▼$356.00$9.41B2.76388,244 shs514,589 shsRAREUltragenyx Pharmaceutical$25.01+0.8%$22.55$18.29▼$42.37$2.44B0.391.66 million shs1.48 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax0.00%+5.10%-0.64%+3.79%+1,535.74%PCVXVaxcyte0.00%-4.67%-2.48%+2.15%+60.86%PRAXPraxis Precision Medicines0.00%-2.05%+4.45%+4.41%+705.67%RAREUltragenyx Pharmaceutical0.00%+3.25%+10.33%-0.12%-36.97%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVXAbivax$123.78+5.7%$116.89$5.59▼$148.83$9.29B0.84834,291 shs1.27 million shsPCVXVaxcyte$55.60-4.9%$58.67$28.09▼$65.00$8.45B1.31.09 million shs2.17 million shsPRAXPraxis Precision Medicines$333.30-1.3%$318.06$34.89▼$356.00$9.41B2.76388,244 shs514,589 shsRAREUltragenyx Pharmaceutical$25.01+0.8%$22.55$18.29▼$42.37$2.44B0.391.66 million shs1.48 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVXAbivax0.00%+5.10%-0.64%+3.79%+1,535.74%PCVXVaxcyte0.00%-4.67%-2.48%+2.15%+60.86%PRAXPraxis Precision Medicines0.00%-2.05%+4.45%+4.41%+705.67%RAREUltragenyx Pharmaceutical0.00%+3.25%+10.33%-0.12%-36.97%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVXAbivax 2.93Moderate Buy$137.1510.80% UpsidePCVXVaxcyte 2.63Moderate Buy$86.0054.69% UpsidePRAXPraxis Precision Medicines 3.00Buy$590.7877.25% UpsideRAREUltragenyx Pharmaceutical 2.83Moderate Buy$60.76142.96% UpsideCurrent Analyst Ratings BreakdownLatest RARE, ABVX, PRAX, and PCVX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2026RAREUltragenyx Pharmaceutical BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$44.00 ➝ $43.004/24/2026RAREUltragenyx Pharmaceutical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026ABVXAbivax Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/16/2026RAREUltragenyx Pharmaceutical Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$50.00 ➝ $67.004/15/2026PRAXPraxis Precision Medicines Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$437.004/14/2026PRAXPraxis Precision Medicines Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$510.004/10/2026PRAXPraxis Precision Medicines Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$815.004/9/2026ABVXAbivax Oddo BhfSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/9/2026PRAXPraxis Precision Medicines Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy4/8/2026PCVXVaxcyte Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/7/2026PRAXPraxis Precision Medicines HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$1,245.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVXAbivaxN/AN/AN/AN/A$6.57 per shareN/APCVXVaxcyteN/AN/AN/AN/A$20.51 per shareN/APRAXPraxis Precision Medicines$8.55M1,086.44N/AN/A$34.85 per share9.56RAREUltragenyx Pharmaceutical$673M3.65N/AN/A($0.83) per share-30.13Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVXAbivax-$380.27M-$5.37N/AN/AN/AN/A-146.43%-88.69%5/25/2026 (Estimated)PCVXVaxcyte-$766.63M-$5.62N/AN/AN/AN/A-25.88%-23.85%5/6/2026 (Estimated)PRAXPraxis Precision Medicines-$303.27M-$13.46N/AN/AN/AN/A-58.74%-53.54%N/ARAREUltragenyx Pharmaceutical-$575M-$5.84N/AN/AN/A-85.54%-1,024.42%-43.10%5/5/2026 (Estimated)Latest RARE, ABVX, PRAX, and PCVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/25/2026Q1 2026ABVXAbivax-$0.9360N/AN/AN/A$0.40 millionN/A5/6/2026Q1 2026PCVXVaxcyte-$1.7411N/AN/AN/A$12.50 millionN/A5/5/2026Q1 2026RAREUltragenyx Pharmaceutical-$1.4968-$1.84-$0.3432$999.00$158.38 millionN/A3/23/2026Q4 2025ABVXAbivax-$2.24-$1.20+$1.04-$1.20$1.80 million$0.52 million2/24/2026Q4 2025PCVXVaxcyte-$1.46-$1.80-$0.34-$1.80$18.75 millionN/A2/19/2026Q4 2025PRAXPraxis Precision Medicines-$3.00-$3.50-$0.50-$3.50$0.26 millionN/A2/14/2026Q4 2025ABVXAbivaxN/A-$1.20N/A-$1.20N/A$0.52 million2/12/2026Q4 2025RAREUltragenyx Pharmaceutical-$1.20-$1.29-$0.09-$1.29$199.60 million$207.28 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVXAbivaxN/AN/AN/AN/AN/APCVXVaxcyteN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ARAREUltragenyx PharmaceuticalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVXAbivaxN/A8.758.75PCVXVaxcyteN/A7.917.91PRAXPraxis Precision MedicinesN/A10.2210.22RAREUltragenyx PharmaceuticalN/A2.482.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVXAbivax47.91%PCVXVaxcyte96.78%PRAXPraxis Precision Medicines67.84%RAREUltragenyx Pharmaceutical97.67%Insider OwnershipCompanyInsider OwnershipABVXAbivaxN/APCVXVaxcyte3.10%PRAXPraxis Precision Medicines2.70%RAREUltragenyx Pharmaceutical5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVXAbivax6179.29 millionN/ANot OptionablePCVXVaxcyte160144.39 million139.91 millionOptionablePRAXPraxis Precision Medicines11027.87 million27.10 millionOptionableRAREUltragenyx Pharmaceutical1,37198.31 million93.20 millionOptionableRARE, ABVX, PRAX, and PCVX HeadlinesRecent News About These CompaniesUltragenyx Pharmaceutical Q1 Earnings Call Highlights1 hour ago | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Releases Earnings Results, Beats Expectations By $1,000.50 EPS4 hours ago | marketbeat.comUltragenyx (RARE) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates4 hours ago | zacks.comUltragenyx (RARE) Reports Q1 Loss, Misses Revenue EstimatesMay 5 at 6:11 PM | zacks.comUltragenyx Reports First Quarter 2026 Financial Results and Corporate UpdateMay 5 at 4:01 PM | globenewswire.comUltragenyx Pharmaceutical (NASDAQ:RARE) CFO Howard Horn Sells 4,683 SharesMay 4 at 7:25 PM | marketbeat.comAnalysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Price Target at $61.18May 4 at 6:03 AM | americanbankingnews.comUltragenyx Pharmaceutical (RARE) to Release Quarterly Earnings on TuesdayMay 3 at 4:04 AM | americanbankingnews.comUltragenyx Pharmaceutical (NASDAQ:RARE) Upgraded to Hold at Wall Street ZenMay 3 at 1:05 AM | marketbeat.comPictet Asset Management Holding SA Trims Stock Holdings in Ultragenyx Pharmaceutical Inc. $RAREMay 1, 2026 | marketbeat.comBarclays Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $43.00April 29, 2026 | marketbeat.comWill Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should KnowApril 29, 2026 | zacks.comUltragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate UpdateApril 29, 2026 | globenewswire.comUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Recommendation of "Moderate Buy" from AnalystsApril 29, 2026 | marketbeat.comWill Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should KnowApril 28, 2026 | zacks.comUltragenyx Pharmaceutical (RARE) Projected to Post Quarterly Earnings on TuesdayApril 28, 2026 | marketbeat.comTeacher Retirement System of Texas Purchases 327,502 Shares of Ultragenyx Pharmaceutical Inc. $RAREApril 26, 2026 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Shares Cross Above 50-Day Moving Average - Here's WhyApril 25, 2026 | marketbeat.comUltragenyx Pharmaceutical (NASDAQ:RARE) Lowered to Sell Rating by Wall Street ZenApril 25, 2026 | marketbeat.comUltragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 24, 2026 | globenewswire.comMassachusetts Financial Services Co. MA Has $7.13 Million Holdings in Ultragenyx Pharmaceutical Inc. $RAREApril 17, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 2026USA Rare Earth's $2.8B Power Play to Secure the Supply ChainBy Jeffrey Neal Johnson | April 23, 20263 Stocks Flashing Rare Buy Signals After the Market's Wildest MonthBy Bridget Bennett | April 21, 2026Investing in Rare Earth Elements: How the REXC ETF Bypasses China’s DominanceBy Jessica Mitacek | April 28, 2026A One-Stop Shop to Track the Magnificent Seven as Big Tech Tries to StabilizeBy Jessica Mitacek | April 7, 2026RARE, ABVX, PRAX, and PCVX Company DescriptionsAbivax NASDAQ:ABVX$123.78 +6.65 (+5.68%) Closing price 04:00 PM EasternExtended Trading$124.00 +0.22 (+0.18%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.Vaxcyte NASDAQ:PCVX$55.60 -2.89 (-4.95%) Closing price 03:59 PM EasternExtended Trading$55.52 -0.08 (-0.15%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Praxis Precision Medicines NASDAQ:PRAX$333.30 -4.31 (-1.28%) Closing price 04:00 PM EasternExtended Trading$333.50 +0.20 (+0.06%) As of 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.Ultragenyx Pharmaceutical NASDAQ:RARE$25.01 +0.20 (+0.81%) Closing price 04:00 PM EasternExtended Trading$24.46 -0.55 (-2.18%) As of 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
